Details
Stereochemistry | MIXED |
Molecular Formula | C22H32N2O6 |
Molecular Weight | 420.5001 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 0 / 2 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
C(CCCNCC(c1ccc(c(c1)O)O)O)CCNCC(c2ccc(c(c2)O)O)O
InChI
InChIKey=OXLZNBCNGJWPRV-UHFFFAOYSA-N
InChI=1S/C22H32N2O6/c25-17-7-5-15(11-19(17)27)21(29)13-23-9-3-1-2-4-10-24-14-22(30)16-6-8-18(26)20(28)12-16/h5-8,11-12,21-30H,1-4,9-10,13-14H2
Molecular Formula | C22H32N2O6 |
Molecular Weight | 420.5001 |
Charge | 0 |
Count |
|
Stereochemistry | MIXED |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 2 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionSources: http://www.ncbi.nlm.nih.gov/pubmed/195789Curator's Comment:: description was created based on several sources, including, http://home.intekom.com/pharm/intramed/ipradinf.html
Sources: http://www.ncbi.nlm.nih.gov/pubmed/195789
Curator's Comment:: description was created based on several sources, including, http://home.intekom.com/pharm/intramed/ipradinf.html
Hexoprenaline is a selective beta2-adrenoreceptor agonist indicated for use in the treatment of bronchospasm associated with obstructive airways diseases, including asthma, bronchitis and emphysema. In many countries the drug is used as tocolytic agent (under the trade name gynipral).
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL210 Sources: http://www.ncbi.nlm.nih.gov/pubmed/195789 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Sources: http://www.ncbi.nlm.nih.gov/pubmed/195789 |
Palliative | Unknown Approved UseUnknown |
||
Primary | Unknown Approved UseUnknown |
|||
Sources: http://www.ncbi.nlm.nih.gov/pubmed/195789 |
Primary | Unknown Approved UseUnknown |
||
Preventing | GYNIPRAL Approved UseGynipral prevents threatened abortion with premature labour. |
PubMed
Title | Date | PubMed |
---|---|---|
[Tocolysis with hexoprenalin and salbutamol in a clinical comparison]. | 1983 Mar |
|
A comparison of the relative toxicities of beta-sympathomimetic tocolytic agents. | 1985 Oct |
|
[Comparison of the cost of treatment of premature labor with atosiban or beta-sympathomimetics from the perspective of the health care payer--a pharmacoeconomic model]. | 2004 Mar |
|
Betamimetics for inhibiting preterm labour. | 2004 Oct 18 |
|
Beta 2-agonist treatment enhances uterine oxytocin receptor mRNA expression in pregnant rats. | 2004 Sep |
|
Arg16 homozygosity of the beta2-adrenergic receptor improves the outcome after beta2-agonist tocolysis for preterm labor. | 2005 Dec |
|
Circulatory corticotropin-releasing hormone mRNA concentrations are increased in women with preterm delivery but not in those who respond to tocolytic treatment. | 2005 Mar |
|
Flow injection potentiometric assay of hexoprenaline in its pure state, pharmaceutical preparations, and biological samples. | 2008 |
|
Treatment of pregnant women with a betamimetic and verapamil increases the micronuclei frequency in umbilical cord blood lymphocytes. | 2008 Aug |
|
Atosiban versus betamimetics in the treatment of preterm labour in Germany: an economic evaluation. | 2009 Jun 19 |
|
Management of foetal asphyxia by intrauterine foetal resuscitation. | 2010 Sep |
|
Dependence of the lymphocyte proliferative response on the endogenous cortisol level and sensitivity to β-adrenergic regulation in vitro in the early period of penetrating eye injury. | 2010 Sep-Oct |
Sample Use Guides
Hexoprenaline can be given by metered aerosol in doses of 200 to 400μg, up to 5 times daily (in asthma), or as an infusion of 0,30 ug and 0,45 ug per minute or as 1-2 tablets q.i.d (0.5 mg per tablet) (maintenance dose in premature labour).
Route of Administration:
Other
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Jun 26 06:13:27 UTC 2021
by
admin
on
Sat Jun 26 06:13:27 UTC 2021
|
Record UNII |
G9L6B3W684
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Systematic Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-ATC |
R03AC06
Created by
admin on Sat Jun 26 06:13:27 UTC 2021 , Edited by admin on Sat Jun 26 06:13:27 UTC 2021
|
||
|
WHO-ATC |
R03CC05
Created by
admin on Sat Jun 26 06:13:27 UTC 2021 , Edited by admin on Sat Jun 26 06:13:27 UTC 2021
|
||
|
WHO-VATC |
QR03CC05
Created by
admin on Sat Jun 26 06:13:27 UTC 2021 , Edited by admin on Sat Jun 26 06:13:27 UTC 2021
|
||
|
WHO-VATC |
QR03AC06
Created by
admin on Sat Jun 26 06:13:27 UTC 2021 , Edited by admin on Sat Jun 26 06:13:27 UTC 2021
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
2650
Created by
admin on Sat Jun 26 06:13:27 UTC 2021 , Edited by admin on Sat Jun 26 06:13:27 UTC 2021
|
PRIMARY | |||
|
3215-70-1
Created by
admin on Sat Jun 26 06:13:27 UTC 2021 , Edited by admin on Sat Jun 26 06:13:27 UTC 2021
|
PRIMARY | |||
|
HEXOPRENALINE
Created by
admin on Sat Jun 26 06:13:27 UTC 2021 , Edited by admin on Sat Jun 26 06:13:27 UTC 2021
|
PRIMARY | |||
|
CHEMBL1589896
Created by
admin on Sat Jun 26 06:13:27 UTC 2021 , Edited by admin on Sat Jun 26 06:13:27 UTC 2021
|
PRIMARY | |||
|
5307
Created by
admin on Sat Jun 26 06:13:27 UTC 2021 , Edited by admin on Sat Jun 26 06:13:27 UTC 2021
|
PRIMARY | RxNorm | ||
|
G9L6B3W684
Created by
admin on Sat Jun 26 06:13:27 UTC 2021 , Edited by admin on Sat Jun 26 06:13:27 UTC 2021
|
PRIMARY | |||
|
DB08957
Created by
admin on Sat Jun 26 06:13:27 UTC 2021 , Edited by admin on Sat Jun 26 06:13:27 UTC 2021
|
PRIMARY | |||
|
D006594
Created by
admin on Sat Jun 26 06:13:27 UTC 2021 , Edited by admin on Sat Jun 26 06:13:27 UTC 2021
|
PRIMARY | |||
|
C170044
Created by
admin on Sat Jun 26 06:13:27 UTC 2021 , Edited by admin on Sat Jun 26 06:13:27 UTC 2021
|
PRIMARY | |||
|
3215-70-1
Created by
admin on Sat Jun 26 06:13:27 UTC 2021 , Edited by admin on Sat Jun 26 06:13:27 UTC 2021
|
PRIMARY | |||
|
3609
Created by
admin on Sat Jun 26 06:13:27 UTC 2021 , Edited by admin on Sat Jun 26 06:13:27 UTC 2021
|
PRIMARY | |||
|
M6013
Created by
admin on Sat Jun 26 06:13:27 UTC 2021 , Edited by admin on Sat Jun 26 06:13:27 UTC 2021
|
PRIMARY | Merck Index | ||
|
SUB08041MIG
Created by
admin on Sat Jun 26 06:13:27 UTC 2021 , Edited by admin on Sat Jun 26 06:13:27 UTC 2021
|
PRIMARY | |||
|
1372
Created by
admin on Sat Jun 26 06:13:27 UTC 2021 , Edited by admin on Sat Jun 26 06:13:27 UTC 2021
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT | |||
|
TARGET -> AGONIST |
SHORT-ACTING
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |